Global "Malaria Vaccines Market" Expected to reach a high CAGR of 33.5% during the forecasting period (2022 - 2029)
Malaria an intermittent and remittent fever caused by a protozoan parasite that invades the red blood cells and is transmitted by mosquitoes in many tropical and subtropical regions and leads to severe illness in both pediatrics and adults.
Pregnant women and pediatrics are more frequently affected by malaria. It is also reported that sickness affected pregnant women who give birth to premature babies or birth to dead infants.
Malaria vaccines are considered amongst the most important modalities for the prevention of malaria disease and the reduction of malaria transmission.
Researchers, clinical trialists, and vaccine developers are focusing on developing many approaches to bring forward the availability of vaccines. This vaccine helps in filling the gaps between various malaria safety measures.
The rapid surge in the incidence of malaria globally and majorly in the African region and an increase in funding by government organizations for the eradication of the disease in the sub-Saharan region is driving the global vaccine market during the forecast period.
R&D initiatives by research organizations for the development of pregnancy-related malaria vaccines and non-government organization funding for new vaccine development by research institutes and pilot programs in the sub-Saharan region are additionally driving the malaria vaccines market during the forecast period.
According to World Health Organisation in 2017, it is estimated that 3.4 billion people in 92 countries globally are at risk of being affected with malaria and developing disease out of which are 1.1 billion are at high risk.
According to WHO in 2017, the burden of malaria epidemiology is most substantial in the African region and estimated that 93% of malaria deaths occurred and in children aged five and below accounted for 61% of all deaths.
In January 2019, a new pregnancy-associated malaria vaccine developed by the University of Copenhagen passed first human trial.
In March 2018, Global Health Innovative Technology Gund awarded the University of Florida and partners in the united states and Japan with 3.2 million to develop an advanced vaccine to prevent transmission of malaria.
Global malaria vaccine market is segmented by vaccine type, agent, and end-users. Vaccine type includes pre-erythrocytic vaccines, blood-stage vaccines, and transmission-blocking vaccines and agent type include Plasmodium falciparum and Plasmodium vivax. End-users include hospitals, clinics, vaccination centers, and community centers.
The pre-erythrocytic vaccines dominate the global malaria vaccines market during the forecast period owing to their extensive usage in vaccination programs due to its efficiency and the clinical advantages provided by vaccines it includes its inherent property of elimination of the infections entirely from the body and others.
The global malaria vaccine market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.
The Middle East and Africa are dominating the global malaria vaccines market during the forecast period owing to the rise in malaria across the emerging regions and various initiatives and funding by government and non-government organizations for eradicating the disease by awareness campaigns, cost-effective vaccines delivery, and vaccination programs.
In April 2017, Gavi the vaccine alliance the global fund to fight Aids, tuberculosis, and malaria, and Unitraid were partnering to provide 49.2 million for the first phase of pilot programs. Ministries of health in Ghana, Kenya, and Malawi will implement the pilot program in coordination with WHO.
New product launches and recent FDA approvals for initiating clinical trials of their novel technology vaccines by critical players are driving the global malaria vaccines market during the forecast period.
On February 4th, 2019, VLP Therapeutics received U.S FDA clearance for initiating clinical trials of its new VLPM01 malaria vaccine.
In March 2018, researchers at Hyderabad based-center for molecular cellular and molecular biology started working on developing whole parasite vaccines that can be conditionally attenuated when given to humans.
In July 2015, the European medical agency committee for medicinal products for human use had adopted a scientific opinion for Mosquirix for use outside the European Union.
Major market players in the malaria vaccines market are VLP Therapeutics, GlaxoSmithKline Plc, Sanaria Inc., Mymetics Corporation, others.
Get your free sample proposal with a single click!